White adipose tissue is now recognised to be a multifunctional organ; in addition to the central role of lipid storage, it has a major endocrine function secreting several hormones, notably leptin and adiponectin, and a diverse range of other protein factors. These various protein signals have been given the collective name 'adipocytokines' or 'adipokines'. However, since most are neither 'cytokines' nor 'cytokine-like', it is recommended that the term 'adipokine' be universally adopted to describe a protein that is secreted from (and synthesised by) adipocytes. It is suggested that the term is restricted to proteins secreted from adipocytes, excluding signals released only by the other cell types (such as macrophages) in adipose tissue. The adipokinome (which together with lipid moieties released, such as fatty acids and prostaglandins, constitute the secretome of fat cells) includes proteins involved in lipid metabolism, insulin sensitivity, the alternative complement system, vascular haemostasis, blood pressure regulation and angiogenesis, as well as the regulation of energy balance. In addition, there is a growing list of adipokines involved in inflammation (TNFa, IL-1b, IL-6, IL-8, IL-10, transforming growth factor-b, nerve growth factor) and the acute-phase response (plasminogen activator inhibitor-1, haptoglobin, serum amyloid A). Production of these proteins by adipose tissue is increased in obesity, and raised circulating levels of several acute-phase proteins and inflammatory cytokines has led to the view that the obese are characterised by a state of chronic low-grade inflammation, and that this links causally to insulin resistance and the metabolic syndrome. It is, however, unclear as to the extent to which adipose tissue contributes quantitatively to the elevated circulating levels of these factors in obesity and whether there is a generalised or local state of inflammation. The parsimonious view is that the increased production of inflammatory cytokines and acute-phase proteins by adipose tissue in obesity relates primarily to localised events within the expanding fat depots. It is suggested that these events reflect hypoxia in parts of the growing adipose tissue mass in advance of angiogenesis, and involve the key controller of the cellular response to hypoxia, the transcription factor hypoxia inducible factor-1.
White adipose tissue (WAT) is the main site of energy storage in mammals and birds, substrate being deposited as triacylglycerols at a high energy density. Until the last decade energy storage was seen as essentially the only role of white fat, apart from providing thermal and mechanical insulation. A revolution has occurred recently, however, in our understanding of the biological function of WAT; the tissue is now seen as a highly dynamic organ, being involved in a wide range of physiological and metabolic processes far beyond the paradigm of fuel storage. This changed perspective has occurred through the recognition that WAT is an endocrine organ; white adipocytes secrete several major hormones, most notably leptin and adiponectin, together with a diverse range of other protein signals and factors. This is in addition to the adipocytes' central role in the deposition and release of fatty acids (Mohamed-Ali et al. 1998; Frühbeck et al. 2001; Trayhurn & Beattie, 2001) .
In the present article we consider one of the key recent developments in the function of white fat, i.e. inflammation and the role of the tissue as a source of proteins characteristic of the inflammatory response. Specific aspects of this area have also been addressed in other recent reviews (Coppack, 2001; Frühbeck et al. 2001; Rajala & Scherer, 2003; Klaus, 2004) . We consider first some important issues of definition and nomenclature which we believe require clarification and agreement.
Definitions: 'adipokines' not 'adipocytokines'?
As the number of protein signals recognised to be secreted from adipose tissue rapidly increased it became helpful to accord them a collective name. The term initially introduced was 'adipocytokines' (Funahashi et al. 1999) , and this has been used extensively. Although the name has merit, it is potentially misleading since there is an inference that the adipocyte-secreted proteins are cytokines, or cytokine-like. While this is the case for some, such as TNFa and IL-6, it is clearly not so with the majority. The alternative name coined is 'adipokines', and this is rather more satisfactory since it does not imply that the proteins belong to a particular functional group. We therefore recommend that the term 'adipokine' be universally adopted to describe a protein that is secreted from (and synthesised by) adipocytes.
Secretion is the critical characteristic of an adipokine, and we emphasise this since the term has also been used in connection with other adipocyte proteins such as adiponutrin (Wiesner et al. 2004) , which is a transmembrane protein rather than a secretory product. 'Adipokine' has also been employed to describe a protein that is secreted by adipose tissue, rather than by adipocytes. However, it is preferable to restrict the term to those proteins that are released by adipocytes themselves. The principal reason for this is that cells such as macrophages which also secrete protein signals are found in a number of organs, as well as being present in adipose tissue (Weisberg et al. 2003; Xu et al. 2003) . There is, therefore, a lack of specificity in giving the secreted proteins a special designation when such cells happen to be within fat depots, even though their presence may well be of considerable functional importance.
There is also a question of whether the term adipokine should be restricted to proteins released from white adipocytes, or include those secreted from brown adipocytes. White and brown adipocytes are functionally different, of course, with the latter being specialised for the production of heat through the presence of the mitochondrial uncoupling protein, UCP-1. In practice, no proteins appear to be secreted from brown adipocytes which are not also released by white fat cells, so in effect this may not be an issue.
Given the current focus on 'omic' approaches in biology (genome, transcriptome, proteome, metabolome/metabonome), the totality of secreted proteins may be described as constituting the adipokinome. Proteins are, however, clearly not the only class of molecule secreted from adipocytes. In addition to fatty acids, which quantitatively are much the largest secretory product, there are other lipid substances, including cholesterol, steroid hormones, prostaglandins and prostanoids, and retinol (neither retinol nor cholesterol are actually synthesised within adipocytes, but are stored and released). The lipid substances and adipokinome together can be said to constitute the 'secretome' of the adipocyte.
Identification of an adipokine
The identification of a protein as an adipokine requires that secretion from adipocytes be demonstrated. In practice, this will generally reflect selective release from adipocytes in vitro. This may be either from freshly isolated adipocytes, or adipocytes derived by differentiation from fibroblastic pre-adipocytes -whether primary culture or from clonal cell lines. Alternative approaches, which are more challenging, include detection of the protein in the venous drainage from WAT at a concentration higher than in arterial blood, or following microdialysis.
The initial stage in the identification of a candidate adipokine is frequently detection of the expression of a gene in adipose tissue, or in adipocytes differentiated in culture. Such a gene may encode either: (i) a product recognised to be secreted from other tissues (for example, IL-6), or (ii) reflect a protein found in the circulation, or (iii) if a novel gene, the derived protein should contain a signal sequence. When expression is first identified in adipose tissue itself, it is essential to determine whether that expression occurs within mature adipocytes or in the other cells that constitute the tissue, either histologically (in situ hybridisation) or by separation of the adipocytes from the stromal vascular fraction by collagenase digestion. Equally, expression in an adipocyte clonal line needs to be verified for the native tissue. Gene expression must, of course, be followed by detection of the encoded protein in adipocytes.
When a protein which is present in the circulation, or recognised to be secreted from other tissues, is synthesised in adipocytes there is an a priori case for it being considered an adipokine. Nevertheless, secretion from the adipocyte needs to be directly demonstrated before such a protein should be accepted as a genuine adipokine.
Adipokines: a diverse group of proteins
The total number of adipokines, both documented and putative, is now well over fifty; the main functional categories are summarised in Fig. 1 . The earliest to be identified was in practice the enzyme lipoprotein lipase, responsible for the hydrolysis of circulating triacylglycerols to NEFA; this was followed in the mid 1980s by adipsin, a serine protease and part of the alternative complement pathway (Cook et al. 1985 (Cook et al. , 1987 . The key development which led to the current focus on adipose tissue as a major site of the secretion of protein signals was, however, the discovery in 1994 of leptin (Zhang et al. 1994) . Leptin, which is a 16 000 molecular-weight cytokine-like hormone with a wide range of biological functions, established adipocytes as endocrine cells. The diversity of the adipokines (Fig. 2) , both in terms of protein structure and of putative function, is considerable (Frühbeck et al. 2001; Trayhurn & Beattie, 2001) . The group includes: classical cytokines (e.g., TNFa, IL-6, IL-8), growth factors (e.g., transforming growth factor-b; TGF-b) and proteins of the alternative complement system (e.g., adipsin, acylation-stimulating protein). The group also includes: proteins involved in vascular haemostasis (e.g., plasminogen activator inhibitor-1 (PAI-1), tissue factor), the regulation of blood pressure (angiotensinogen), lipid metabolism (e.g., retinol-binding protein, cholesteryl ester transfer protein), glucose homeostasis (e.g., adiponectin, possibly resistin) and angiogenesis (e.g., vascular endothelial growth factor; VEGF), as well as acute-phase and stress responses (e.g., haptoglobin, metallothionein).
From the wide range of protein signals and factors already identified, it is evident that WAT is a secretory and endocrine organ of considerable complexity which is highly integrated into the overall physiological and metabolic control systems of mammals. It is not easy to put forward a coherent framework for why such a diversity of factors is secreted by white adipocytes. However, one hypothesis would be that the various factors may relate ultimately to the central lipid storage and release function of the tissue (Trayhurn & Beattie, 2001) . A corollary to the secretion of such a wide range of adipokines is that WAT has an extensive system for communication with other tissues and organs. Co-culture studies have indicated, for example, that adipocytes directly signal to other tissues such as skeletal muscle and the adrenal cortex (Dietze et al. 2002; Ehrhart-Bornstein et al. 2003) . There is also, in particular, a distinct cross-talk between white adipocytes and the brain through leptin and the sympathetic nervous system (Rayner & Trayhurn, 2001) .
Inflammation and obesity
An important recent development in our understanding of obesity is the emergence of the concept that it (and diabetes) is characterised by a state of chronic low-grade inflammation (Yudkin et al. 1999; Das, 2001; Festa et al. 2001; Engström et al. 2003) . The basis for this view is that increased circulating levels of several markers of inflammation, both pro-inflammatory cytokines and acute-phase proteins, are elevated in the obese; these markers include IL-6, the TNFa system, C-reactive protein (CRP) and haptoglobin (Das, 2001; Bulló et al. 2003) . The implications in terms of the site of inflammation itself, whether systemic or local, are unclear. Nevertheless, it is increasingly evident that the inflammatory state may be causal in the development of insulin resistance and the other disorders associated with obesity, such as hyperlipidaemia and the metabolic syndrome (Hotamisligil, 2003; Yudkin, 2003) . While the general assumption is that inflammation is consequent to obesity, it has been suggested that obesity is in fact a result of inflammatory disease (Das, 2001) .
A central question is the origin of the inflammatory markers in obesity, and there are three possibilities. The first is that it reflects production and release from organs other than adipose tissue, primarily the liver (and immune cells). The second explanation is that WAT is secreting factors that stimulate the production of inflammatory markers from the liver and other organs; this may well be the case with CRP, where it is argued that hepatic production is stimulated by increased IL-6 from the expanded fat mass of the obese (Yudkin et al. 2000; Yudkin, 2003) . The third possibility is that adipocytes themselves are the immediate source of some, or most, of these inflammatory markers, raised circulating levels in obesity reflecting production from the increased WAT mass. There is also, of course, the possibility of there being a combination of production in adipose tissue and other organs.
From the perspective of adipose tissue biology, a key question is whether adipocytes (or adipose tissue) directly contribute to the raised circulating levels of specific inflammatory markers and, if so, to what extent? Although obtaining quantitative information on the contribution from particular cells within adipose tissue is difficult, the issue that can be readily addressed is whether adipocytes express certain inflammatory genes and their encoded proteins secreted. Recent reports demonstrating that WAT is infiltrated by macrophages in obesity clearly suggest that the non-adipocyte fraction may be a significant component of the inflammatory state within adipose tissue (Weisberg et al. 2003; Xu et al. 2003) .
Cytokines
Tumour necrosis factor-a and interleukin-6
Several inflammatory cytokines are now recognised to be expressed in, and secreted by, white adipocytes, the first to be identified being TNFa (Hotamisligil et al. 1993) . TNFa expression in WAT was initially demonstrated in rodents, and found to be markedly increased in obese models (Hotamisligil et al. 1993) . From this it was proposed that TNFa is linked to the development of insulin resistance. The cytokine has been extensively examined in relation to insulin action, and multiple effects have been described, including the inhibition of the insulin receptor signalling pathway (Coppack, 2001; Hotamisligil, 2003) . In man, the secretion of TNFa is reported to be mainly due to the cells of the stromal vascular and matrix fractions, including the macrophages, despite the fact that previously most of the mRNA for TNFa was thought to be found within the adipocytes themselves (Weisberg et al. 2003; Fain et al. 2004a ). An apparent disparity between mRNA and protein secretion in human WAT is evident for several adipokines in recent reports by Fain et al. (2004a,b) and requires further examination.
TNFa is a powerful local regulator within adipose tissue, acting in both an autocrine and a paracrine manner to influence a range of processes, including apoptosis (Prins et al. 1997; Coppack, 2001 ). There appears to be a hierarchy of cytokines within WAT, with TNFa playing a pivotal role in relation to the production of several cytokines and other adipokines (Coppack, 2001 ). Thus, for example, TNFa is a key regulator of the synthesis of IL-6, of the acute-phase protein, haptoglobin (Chiellini et al. 2002 ; Oller do Nascimento et al. 2004), and of the neurotrophin, nerve growth factor (NGF; Peeraully et al. 2004) . The extent to which TNFa produced in WAT is released into the circulation has been a matter of debate, but a relationship between the plasma TNFa system (including the soluble receptors) and indices of obesity has been reported (Bulló et al. 2003) .
The other cytokine that has been the subject of major interest in WAT is IL-6. It is expressed in, and secreted by, adipocytes and although it has local actions within the tissue, it is released into the circulation (Mohamed-Ali et al. 1997) . Both plasma levels of IL-6 and expression in WAT are elevated in obesity and insulin resistance (Mohamed-Ali et al. 1997; Bastard et al. 2000; Vozarova et al. 2001) . It has been proposed that IL-6 has direct central actions, as IL-6 receptors are found in the hypothalamus in mice (Mohamed-Ali et al. 1997; Wallenius et al. 2002) . As such, it is a candidate molecule for conveying information from adipocytes to the hypothalamus in the regulation of energy balance, additional to leptin.
Other cytokines
Although there has been considerable focus on TNFa and IL-6, several other cytokines and related factors are synthesised within adipose tissue, including IL-1b, TGF-b and, of course, leptin. Recent reports have included IL-8, IL-10 and IL-17D. The IL-8 gene is expressed in human adipocytes and the protein released from both fat cells and adipose tissue fragments (Bruun et al. 2000 (Bruun et al. , 2001 . IL-1b and TNFa stimulate IL-8 release, while dexamethasone is inhibitory (Bruun et al. 2001) . As with IL-6, the plasma level of IL-8 is increased in obesity (Straczkowski et al. 2002) .
Circulating levels of IL-18 are also increased in obesity and fall with weight reduction (Esposito et al. 2002) . As a consequence, it is speculated that WAT is a probable site of production of IL-18. Although there are no published reports on this, we have recently observed IL-18 gene expression in human WAT (IS Wood and P Trayhurn, unpublished results). Similarly, the levels of IL-10, an anti-inflammatory cytokine, are also raised in the obese (Esposito et al. 2003) ; the secretion of IL-10 from human adipocytes, as well as from the stromal vascular fraction and tissue matrix of human fat depots, has been reported (Fain et al. 2004b ).
The expression of IL-17D, believed to be the last member of the IL-17 family to be identified, has recently been described in (human?) adipocytes (Starnes et al. 2002) .
This cytokine stimulates the production of IL-6 and IL-8 from endothelial cells (Starnes et al. 2002) . However, its release from adipocytes has not been documented, so at present it can only be considered as a putative adipokine.
Acute-phase proteins
There are a number of acute-phase proteins whose plasma concentration increases substantially during the early stages of the inflammatory response, and a small number where the level falls (Gabay & Kushner, 1999) . Several of these proteins are now recognised as adipokines, with adipose tissue being a potential contributor (either major or minor) to the raised circulating levels in obesity; recently described examples are summarised here. Expression of the genes encoding some acute-phase reactants, such as a1-acid glycoprotein and 24p3, has been observed in either adipocyte cell culture or in murine tissues Lin et al. 2001 ), but secretion as such has not yet been reported.
Plasminogen activator inhibitor-1
PAI-1 is an important factor in the maintenance of vascular haemostasis, inhibiting the activation of plasminogen, the precursor of plasmin, which is involved in the breakdown of fibrin (Mutch et al. 2001) . The expression and secretion of PAI-1 by adipocytes, both rodent and human, is well documented (Lundgren et al. 1996; Eriksson et al. 1998; Cigolini et al. 1999; Mutch et al. 2001) . The circulating level of PAI-1 is increased in obesity and synthesis in WAT is also raised (Alessi et al. 2000) . This has led to the view that adipose tissue is the major source of the elevated PAI-1 levels in the obese (Lundgren et al. 1996; Samad et al. 1996; Alessi et al. 2000) . As the risk of atherothrombotic disease is increased in obesity, this is a potent example of how the co-morbidities, such as diabetes and cardiovascular risk, associated with a high body fat can be directly linked to alterations in the production of specific adipokines. In addition to its role in haemostasis, PAI-1 is also an acute-phase response protein, the levels rising in inflammation (Gabay & Kushner, 1999) .
Haptoglobin
Several studies have now reported that the haptoglobin gene is expressed in murine adipose tissue (Friedrichs Fig. 2 . Inflammatory and acute-phase response proteins secreted from adipocytes. The proteins in red have been clearly identified as adipokines (i.e. shown to be released by adipocytes) while those in blue are putative adipokines. CRP, C-reactive protein; IL, interleukin; NGF, nerve growth factor; PAI-1, plasminogen activator inhibitor-1; TGF-b, transforming growth factor-b; TNF-a, tumour necrosis factor-a; MCP-1, monocyte chemoattractant protein 1. et al. 1995; Chiellini et al. 2002; Oller do Nascimento et al. 2004) . Similarly, gene expression has also been shown in human WAT (Oller do Nascimento et al. 2004) . A very recent study has demonstrated direct release of haptoglobin from human adipose tissue explants (Fain et al. 2004a ) and release of haptoglobin into the medium has been observed in 3T3-L1 adipocytes by a proteomic approach (Kratchmarova et al. 2002) . Both transgenic studies and studies on 3T3-L1 adipocytes indicate that TNFa is a key factor in the stimulation of haptoglobin expression (Chiellini et al. 2002; Chinetti et al. 2003; Oller do Nascimento et al. 2004) , with IL-6 also being stimulatory.
Stimulation of the PPARg nuclear receptor through the administration of the thiazolidienedione, rosiglitazone, strongly inhibits haptoglobin gene expression (Oller do Nascimento et al. 2004) . This is consistent with the emerging view that PPARs have substantial anti-inflammatory actions (Moller & Berger, 2003) . Indeed, several other inflammation-related adipokines are down regulated by PPARg ligands, including TNFa, leptin and NGF, while there is evidence that adiponectin is up regulated (Moller & Berger, 2003) .
Serum amyloid A
Serum amyloid A (SAA), the precursor to amyloid A protein found in secondary amyloid plaques, consists of a family of apolipoproteins which bind to, and substitute for, apo A-I in HDL. These apolipoproteins are expressed as either major acute-phase reactants SAA, or constitutive SAA, the functions of which are largely unknown. However, a few clinically important functions have been suggested that include pro-inflammatory and anti-inflammatory roles. A number of genes have now been identified in man and mice which share very similar sequence identities and genomic organisation (Uhlar & Whitehead, 1999) . These genes are up regulated by pro-inflammatory cytokines such as TNFa and IL-6, as well as by glucocorticoids. The expression of SAA, as with other acute-phase reactants, is predominantly in the liver. However, extrahepatic expression of SAA, including adipocytes, has been reported; expression and release of SAA3 occurs in murine adipocytes, and this is up regulated under hyperglycaemic conditions (Lin et al. 2001) .
C-reactive protein
The circulating level of CRP rises with BMI (Visser et al. 1999; Pannacciulli et al. 2001; Bulló et al. 2003) , and elevated levels of this inflammatory marker have been associated with both obesity and diabetes, falling with weight loss (Tchernof et al. 2002) . There is evidence from a study using real-time PCR that the gene encoding CRP is expressed in adipose tissue, an inverse correlation between the levels of the mRNA for CRP and adiponectin being apparent (Ouchi et al. 2003) . This raises the possibility that adipose tissue contributes directly to the circulating pool of CRP. Unfortunately, it is not clear whether CRP expression in adipocytes is in practice significant; our own studies using conventional RT-PCR have found that there is little expression in human WAT, or adipocytes (IS Wood and P Trayhurn, unpublished results). It should be noted that murine CRP is not regarded as an acutephase protein due to its very low expression (Volanakis, 2001) .
Very low levels of expression would suggest that adipocytes are unlikely to be a significant direct contributor to circulating CRP levels. However, IL-6 is secreted by adipose tissue in increased amounts in obesity, as noted earlier, and this is the major cytokine regulating the hepatic production of CRP (Heinrich et al. 1990; Yudkin et al. 2000) . Thus WAT may be a major player in the raised circulating levels of CRP in obesity, but through the indirect route of adipocyte-derived IL-6.
Additional inflammation-related proteins
There are several other adipokines involved in the inflammatory response that are neither cytokines nor acute-phase proteins. Interestingly, adiponectin (also known as Acrp30, AdipoQ, ApM1 or GBP28), which is synthesised only in adipose tissue, appears to have an anti-inflammatory effect, inhibiting phagocytic activity and TNFa production in macrophages Yokota et al. 2000) . This adipokine is now very much centre stage; this is partly because, in contrast to many other adipokines, its expression and release fall in obesity Hotta et al. 2000) . However, the principal reason for the recent focus on adiponectin is the evidence that it is involved in modulating insulin sensitivity (Berg et al. 2001; Yamauchi et al. 2001) , as well as having anti-atherogeneic properties (Engeli et al. 2003) .
We have recently observed that the target-derived neurotrophin, NGF, is synthesised by the main adipose tissue depots in both rodents and man, and is secreted from white adipocytes (Peeraully et al. 2004 ). This protein, which was the first of the family of neurotrophins to be discovered, was originally linked to the growth and survival of sympathetic neurones; however, although not a cytokine, it is now recognised as also being involved in immune and inflammatory responses (Levi-Montalcini et al. 1996; Vega et al. 2003) . Indeed, NGF is expressed in adipocytes specifically associated with wound healing and with atherosclerotic lesions (Hasan et al. 2000; Chaldakov et al. 2001) . Importantly, TNFa has a strong stimulatory effect on NGF gene expression and NGF release from 3T3-L1 adipocytes, suggesting that the neurotrophin is an inflammatory response protein in adipose tissue (Peeraully et al. 2004) .
Why inflammation in obesity: a response to hypoxia?
Much attention has been directed towards unravelling the pathological and clinical implications of inflammation in obesity, and establishing the links with insulin resistance and other metabolic disorders -the metabolic syndrome. However, a central issue is why does WAT release proinflammatory cytokines and acute-phase proteins, and why do these rise sharply as fat mass increases? Linked to this is the question of why obesity should be associated with chronic low-grade inflammation. Adipose tissue may, of course, be contributing inflammation-related factors to a specific site of inflammation in an organ (or organs) elsewhere, or as part of a systemic state of inflammation. However, an alternative view is that the inflammatory state is mainly within WAT itself. If the inflammatory response is primarily local to adipose tissue, at least in terms of its initiation, then the elevated circulating levels of inflammation-related products may in effect reflect spillover from the tissue, and the link with insulin resistance would be an incidental consequence.
In the absence of any specific indication to the contrary, the parsimonious view is that the secretion of inflammatory cytokines and acute-phase proteins by adipocytes in obesity relates to events within WAT itself. If this is correct, what could be the rationale for a local effect? A possible explanation is that it is a response to hypoxia in areas of the fat depots as the tissue mass increases during the progressive development of obesity. The sequence of events might be that as the tissue expands, the vasculature (which is less extensive in WAT than in brown fat) is insufficient to maintain normoxia throughout the organ. Clusters of adipocytes then become relatively hypoxic, and an inflammatory response ensues which serves to increase blood flow and to stimulate angiogenesis. This has some parallels with tumour growth in cancer. That vascular development is an important issue in WAT function is indicated by the fact that adipose tissue mass is sensitive to angiogenesis inhibitors and can be regulated by its vasculature (Rupnick et al. 2002) , and that several angiogenic factors are secreted by adipocytes (Claffey et al. 1992; Rupnick et al. 2002; Lolmede et al. 2003) . These factors include recognised angiogenic signals (VEGF, PAI-1 and leptin), as well as putative signals such as metallothionein and haptoglobin.
A pivotal signal in the cellular response to hypoxia is hypoxia-inducible factor-1 (HIF-1); this transcription factor is a heterodimeric protein consisting of a and b subunits. The b subunit is constitutively expressed, but the a subunit is highly induced by hypoxia leading to the formation of functional HIF-1 (Semenza, 2001; Wenger, 2002; Höpfl et al. 2004) . Hypoxia is characteristic of tumours, where HIF-1 expression is increased, as well as in other disorders such as ischaemic heart disease (Binley et al. 2003; Höpfl et al. 2004) . A number of genes are regulated by HIF-1, which acts as a central controller of oxygen-regulated gene expression. The transcription factor is stabilised and its expression stimulated by cytokines such as TNFa and IL-1b (Hellwig-Bürgel et al. 1999) . The target genes for HIF-1 include VEGF and PAI-1 (Höpfl et al. 2004 ). In addition, there is now evidence for the transcriptional activation of leptin through HIF-1a in response to hypoxia (Ambrosini et al. 2002) .
Immunoreactive HIF-1a has been reported in 3T3-F442A adipocytes and hypoxia results in an increase in the amount of the protein in the cultured cells (Lolmede et al. 2003) . Furthermore, hypoxia leads to an induction of leptin and VEGF expression in these adipocytes, raising the likelihood that a low oxygen tension leads to the stimulation of angiogenesis in adipose tissue through the HIF-1 pathway (Lolmede et al. 2003) .
HIF-1a expression is not just a feature of cultured adipocytes, since we have recently observed that the HIF-1a gene is expressed in mouse WAT depots. Expression occurs in both the adipocytes and in the stromal vascular cells, and in the WAT of obese (ob/ob) mice the level of the mRNA is markedly increased compared with lean siblings (L Hunter, IS Wood and P Trayhurn, unpublished results) . Thus a link between the increased WAT mass in obesity, adipocyte hypoxia, inflammation and the stimulation of angiogenesis is plausible.
Other key developments
We have focused in the present paper on the role of WAT in inflammatory responses. There have, however, been a number of other important recent developments in the adipokine field. For example, a recent report has indicated that human white adipocytes secrete mineralocorticoid-releasing factors, aldosterone secretion by adrenocortical cells being stimulated (Ehrhart-Bornstein et al. 2003) . These results indicate a direct link between obesity and hypertension through adipose tissue regulating mineralocorticoid production.
There is continuing interest in whether adipocytes secrete centrally acting signals in the regulation of appetite and energy balance additional to leptin, as noted earlier. An initial candidate for such a role was fasting-induced adipose factor (also known as PPARg angiopoietin-related gene) (Kersten et al. 2000; Yoon et al. 2000) . Fastinginduced adipose factor is an angiopoietin-related protein, the expression of which is strongly stimulated by fasting in a manner which may be reciprocal to leptin. Fastinginduced adipose factor is potentially of considerable interest, not only as a putative signal in energy balance, but as part of the adaptive response to nutritional deprivation. In this regard, since it is induced by fasting, it is a positive signal of the fasted state, in contrast to leptin which signals food deprivation through a reduction in its expression (Ahima et al. 1996 ).
An intriguing report using DNA microarrays for gene expression profiling of human visceral adipose tissue has suggested that a constellation of neuroendocrine factors may be produced by white adipocytes . These factors included cholecystokinin, neurotensin and neuropeptide Y. If correct, it suggests that the adipocyte is even more remarkable as a secretory cell than currently envisaged; indeed, it would be a veritable powerhouse in the secretion of neuroendocrine signals. However, our attempts to identify transcripts of some of these genes using conventional RT -PCR have proved unsuccessful (L Hunter, IS Wood and P Trayhurn, unpublished results), and the reported expression may in practice reflect the problems inherent in setting a suitable (arbitrary) threshold in microarray studies when comparisons between groups are not part of the experimental paradigm.
Conclusions
The biology of WAT seems ever more rich and complex. The family of adipokines is increasing rapidly, these proteins being highly diverse in structure and in function. A critical issue is the physiological role that many of them play. The role may be local (through an autocrine or paracrine function) or endocrine, or involve multiple levels (as with leptin and IL-6). An important development is the recognition of the extensive and direct involvement of white adipocytes in inflammation and the acute-phase response. In some cases it seems probable that adipocytes contribute substantially to the raised circulating levels of particular pro-inflammatory cytokines and acute-phase reactants in obesity, such as IL-6, PAI-1 and haptoglobin. In others, adipose tissue appears to have an indirect role; for example, hepatic production of CRP may be stimulated by the increased release of IL-6 from adipocytes.
The inflammatory state that is characteristic of obesity may primarily relate to local events within adipose tissue, raised circulating levels of inflammatory cytokines and acute-phase proteins that are adipokines reflecting spillover from the tissue. Hypoxia consequent upon the expansion of white fat mass in advance of angiogenesis could be a key trigger for the inflammation-related events in WAT in obesity. Adipose-derived inflammatory cytokines may lead to a direct stimulation of angiogenic factors, such as VEGF and leptin, as well as through the activation of HIF-1, the central controller of the cellular response to hypoxia.
